Synthesis and delivery of short, noncoding RNA by B lymphocytes

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 50, 2013, Pages 20182-20187

  Almanza, Gonzalo ^a   Anufreichik, Veronika ^a   Rodvold, Jeffrey J ^a   Chiu, Kevin T ^a   DeLaney, Alexandra ^a   Akers, Johnny C ^b   Chen, Clark C ^b   Zanetti, Maurizio ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Immunotherapy; Microvesicles

Indexed keywords

LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MICRORNA; MICRORNA 150; PLASMID DNA; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; UNTRANSLATED RNA; VIRUS NUCLEOPROTEIN;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; BIOGENESIS; CD8+ T LYMPHOCYTE; CELLULAR SECRETION; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DOWN REGULATION; GENE DOSAGE; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; RNA SYNTHESIS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 84890289928     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1311145110     Document Type: Article

References (45)

1. Bartel DP (2004) MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116(2):281-297.
2. Thomas M, Lieberman J, Lal A (2010) Desperately seeking microRNA targets. Nat Struct Mol Biol 17(10):1169-1174.
3. Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1):92-105.
4. Ambros V (2004) The functions of animal microRNAs. Nature 431(7006):350-355.
5. Pedersen I, David M (2008) MicroRNAs in the immune response. Cytokine 43(3):391-394.
6. O'Connell RM, Rao DS, Baltimore D (2012) microRNA regulation of inflammatory responses. Annu Rev Immunol 30:295-312.
7. Volinia S, et al. (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103(7):2257-2261.
8. Cullen BR (2009) Viral and cellular messenger RNA targets of viral microRNAs. Nature 457(7228):421-425.
9. van Rooij E, et al. (2007) Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316(5824):575-579.
10. Krützfeldt J, et al. (2005) Silencing of microRNAs in vivo with 'antagomirs' Nature 438(7068):685-689.
11. Seow Y, Wood MJ (2009) Biological gene delivery vehicles: beyond viral vectors. Mol Ther 17(5):767-777.
12. Alvarez-Erviti L, et al. (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29(4):341-345.
13. Sutkowski N, Kuo ML, Varela-Echavarria A, Dougherty JP, Ron Y (1994) A murine model for B-lymphocyte somatic cell gene therapy. Proc Natl Acad Sci USA 91(19):8875-8879.
14. Xiong S, Gerloni M, Zanetti M (1997) In vivo role of B lymphocytes in somatic transgene immunization. Proc Natl Acad Sci USA 94(12):6352-6357.
15. Zanetti M, Castiglioni P, Rizzi M, Wheeler M, Gerloni M (2004) B lymphocytes as antigen-presenting cell-based genetic vaccines. Immunol Rev 199(June):264-278.
16. Gerloni M, Rizzi M, Castiglioni P, Zanetti M (2004) T cell immunity using transgenic B lymphocytes. Proc Natl Acad Sci USA 101(11):3892-3897.
17. Bogerd HP, et al. (2010) A mammalian herpesvirus uses noncanonical expression and processing mechanisms to generate viral MicroRNAs. Mol Cell 37(1):135-142.
18. Kincaid RP, Burke JM, Sullivan CS (2012) RNA virus microRNA that mimics a B-cell oncomiR. Proc Natl Acad Sci USA 109(8):3077-3082.
19. Almanza G, et al. (2010) Selected microRNAs define cell fate determination of murine central memory CD8 T cells. PLoS One 5(6):e11243.
20. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF (2007) miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci USA 104(17):7080-7085.
21. Jiang X, et al. (2012) Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell 22(4):524-535.
22. Ma Y, et al. (2012) miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut 61(10):1447-1453.
23. Akers JC, Gonda D, Kim R, Carter BS, Chen CC (2013) Biogenesis of extracellular vesicles (EV): Exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J Neurooncol 113(1):1-11.
24. Bevan MJ (1976) Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med 143(5):1283-1288.
25. Kurts C, Robinson BW, Knolle PA (2010) Cross-priming in health and disease. Nat Rev Immunol 10(6):403-414.
26. Clarke SR, et al. (2000) Characterization of the ovalbumin-specific TCR transgenic line OT-I:MHC elements for positive and negative selection. Immunol Cell Biol 78(2):110-117.
27. Moskophidis D, Kioussis D (1998) Contribution of virus-specific CD8+ cytotoxic T cells to virus clearance or pathologic manifestations of influenza virus infection in a T cell receptor transgenic mouse model. J Exp Med 188(2):223-232.
28. Kim SK, Reed DS, Heath WR, Carbone F, Lefrançois L (1997) Activation and migration of CD8 T cells in the intestinal mucosa. J Immunol 159(9):4295-4306.
29. Monticelli S, et al. (2005) MicroRNA profiling of the murine hematopoietic system. Genome Biol 6(8):R71.
30. Kohlhaas S, et al. (2009) Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol 182(5):2578-2582.
31. Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci USA 103(33):12481-12486.
32. Lu J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature 435(7043):834-838.
33. Calin GA, et al. (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 353(17):1793-1801.
34. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6(11):857-866.
35. Garzon R, Calin GA, Croce CM (2009) MicroRNAs in cancer. Annu Rev Med 60:167-179.
36. Costinean S, et al. (2006) Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA 103(18):7024-7029.
37. Zhao JL, et al. (2011) NF-kappaB dysregulation in microRNA-146a-deficient mice drives the development of myeloid malignancies. Proc Natl Acad Sci USA 108(22):9184-9189.
38. Tavazoie SF, et al. (2008) Endogenous human microRNAs that suppress breast cancer metastasis. Nature 451(7175):147-152.
39. Tili E, et al. (2011) Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci USA 108(12):4908-4913.
40. Fabbri M, et al. (2012) MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci USA 109(31):E2110-E2116.
41. Valadi H, et al. (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9(6):654-659.
42. Raposo G, et al. (1996) B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183(3):1161-1172.
43. Pegtel DM, et al. (2010) Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci USA 107(14):6328-6333.
44. Zanetti M (2003) Protocol #0207-545: A phase I/II, escalating dose, open-label evaluation of safety, feasibility, and tolerability of transgenic lymphocyte immunization (TLI) vaccine subjects with histologically proven prostate adenocarcinoma. Hum Gene Ther 14(3):301-302.
45. Morrison SL (1985) Transfectomas provide novel chimeric antibodies. Science 229(4719):1202-1207.